Related references
Note: Only part of the references are listed.Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
Daniele Focosi et al.
ANTIVIRAL RESEARCH (2022)
Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2
Sanjay Kumar Dey et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
R. L. Gottlieb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Newly synthesized series of oxoindole-oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies
Rana M. El-Masry et al.
NEW JOURNAL OF CHEMISTRY (2022)
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
Awadhesh Kumar Singh et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2022)
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
Hong-jie Qian et al.
ACTA PHARMACOLOGICA SINICA (2022)
Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
Janos Andras Motyan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Are COVID surges becoming more predictable? New Omicron variants offer a hint
Ewen Callaway
NATURE (2022)
A DELUGE OF NEW DRUGS FOR COVID
Heidi Ledford
NATURE (2022)
Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report
Marios Prikis et al.
TRANSPLANTATION PROCEEDINGS (2022)
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
Nada A. Ashour et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
Rong Xiang et al.
ACTA PHARMACEUTICA SINICA B (2022)
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian et al.
FRONTIERS IN IMMUNOLOGY (2022)
Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open- label, single-center phase 3 randomized clinical trial
Jiro Terada et al.
ECLINICALMEDICINE (2022)
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 The Ivermectin in COVID Nineteen Study
Juliana Cepelowicz Rajter et al.
CHEST (2021)
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Yan Lou et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Characteristics of SARS-CoV-2 and COVID-19
Ben Hu et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein**
Deborah K. Shoemark et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
Yuanchao Xie et al.
CELL RESEARCH (2021)
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
Patricia R. M. Rocco et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
Yuanyuan Qiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules
Kirill Gorshkov et al.
ACS INFECTIOUS DISEASES (2021)
High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance
Aditya K. Padhi et al.
ISCIENCE (2021)
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
Vicky Mody et al.
COMMUNICATIONS BIOLOGY (2021)
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Wendy P. Painter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2
Chih-Jung Kuo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
Steven S. Good et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Masoud Solaymani-Dodaran et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Zarir F. Udwadia et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial
Eduardo Lopez-Medina et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl et al.
NATURE (2021)
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony C. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Kris M. White et al.
SCIENCE (2021)
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
Rory D. de Vries et al.
SCIENCE (2021)
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Jerzy Osipiuk et al.
NATURE COMMUNICATIONS (2021)
Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
Ewelina Weglarz-Tomczak et al.
SCIENTIFIC REPORTS (2021)
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
Kas Steuten et al.
ACS INFECTIOUS DISEASES (2021)
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
Markus Hoffmann et al.
EBIOMEDICINE (2021)
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
Ross Martin et al.
ANTIVIRAL RESEARCH (2021)
SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment
Adam Stasiulewicz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
Rana Abdelnabi et al.
EBIOMEDICINE (2021)
β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Shuntai Zhou et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
Shuofeng Yuan et al.
NATURE (2021)
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
Luca Braga et al.
NATURE (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Molnupiravir in COVID-19: A systematic review of literature
Awadhesh Kumar Singh et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Jordi Rodon et al.
FRONTIERS IN PHARMACOLOGY (2021)
Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein- Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
Damir Bojadzic et al.
ACS INFECTIOUS DISEASES (2021)
Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance
Alfredo Mari et al.
MICROORGANISMS (2021)
Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial
Gilmar Reis et al.
JAMA NETWORK OPEN (2021)
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase
Souradeep Basu et al.
BIOCHEMICAL JOURNAL (2021)
Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
Liming Yan et al.
CELL (2021)
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H. Khoo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
Rana Abdelnabi et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients
Saeed Kalantari et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
In silico Studies on the Interaction Between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives
Pablo Andrei Nogara et al.
MOLECULAR INFORMATICS (2021)
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou et al.
NATURE MEDICINE (2021)
Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate
Olga Bobileva et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
Agnieszka M. Szemiel et al.
PLOS PATHOGENS (2021)
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection
Yu Ling Tan et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors
Tomas Otava et al.
ACS INFECTIOUS DISEASES (2021)
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
Augusto Di Castelnuovo et al.
FRONTIERS IN MEDICINE (2021)
被撤回的出版物: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial (Publication with Expression of Concern. See vol. 8, 2022) (Retracted article. See vol. 9, 2022)
John McCoy et al.
FRONTIERS IN MEDICINE (2021)
Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
Eric J. Niesor et al.
ACS OMEGA (2021)
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
Jin-Lan Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization
Mohammed I. A. Hamed et al.
RSC ADVANCES (2021)
After the pandemic: perspectives on the future trajectory of COVID-19
Amalio Telenti et al.
NATURE (2021)
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
Vibeke Backer et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
In silico identification of potential SARS COV-2 2′-O-methyltransferase inhibitor: fragment-based screening approach and MM-PBSA calculations
Mahmoud A. El Hassab et al.
RSC ADVANCES (2021)
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial
Jesper D. Gunst et al.
ECLINICALMEDICINE (2021)
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Yuling Han et al.
NATURE (2021)
The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta 1 heterodimer
Sundy N. Y. Yang et al.
ANTIVIRAL RESEARCH (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
Shuai Xia et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Shuai Xia et al.
CELL RESEARCH (2020)
The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients
Jing Yuan et al.
INFLAMMATION RESEARCH (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Fabrizio Cantini et al.
JOURNAL OF INFECTION (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Yan Gao et al.
SCIENCE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou et al.
NATURE COMMUNICATIONS (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
Interferon-α2b Treatment for COVID-19
Qiong Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
Cynthia Liu et al.
ACS CENTRAL SCIENCE (2020)
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Denisa Bojkova et al.
NATURE (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon et al.
NATURE (2020)
Structural basis of receptor recognition by SARS-CoV-2
Jian Shang et al.
NATURE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Xi Wang et al.
CELL DISCOVERY (2020)
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Ehud Chorin et al.
NATURE MEDICINE (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Joshua Geleris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
Natalia Fintelman-Rodrigues et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly et al.
ANTIVIRAL RESEARCH (2020)
Current and future therapeutical approaches for COVID-19
Yongtao Duan et al.
DRUG DISCOVERY TODAY (2020)
Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer
Tie Zhou et al.
EUROPEAN JOURNAL OF CANCER (2020)
Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex
James Chen et al.
CELL (2020)
A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study
Zhigang Ren et al.
ADVANCED SCIENCE (2020)
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review
W. Joost Wiersinga et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
Jun Chen et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
Arun Bahadur Gurung et al.
JOURNAL OF KING SAUD UNIVERSITY SCIENCE (2020)
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
Abdo A. Elfiky
LIFE SCIENCES (2020)
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
Markus Hoffmann et al.
NATURE (2020)
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva et al.
NATURE (2020)
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse et al.
NATURE (2020)
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
Donghyuk Shin et al.
NATURE (2020)
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
Theresa Klemm et al.
EMBO JOURNAL (2020)
Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2
Yuan-Lin Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Jack Major et al.
SCIENCE (2020)
Distinct conformational states of SARS-CoV-2 spike protein
Yongfei Cai et al.
SCIENCE (2020)
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
Mizuki Yamamoto et al.
VIRUSES-BASEL (2020)
Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin
Petra Krafcikova et al.
NATURE COMMUNICATIONS (2020)
Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
Ya-Wen Cheng et al.
CELL REPORTS (2020)
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design
Wioletta Rut et al.
SCIENCE ADVANCES (2020)
Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
Ryan M. Samuel et al.
CELL STEM CELL (2020)
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
Yueping Li et al.
MED (2020)
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L
Michael Dominic Sacco et al.
SCIENCE ADVANCES (2020)
An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19
Jonathan H. Shrimp et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein
Chan Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Bo Ram Beck et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Robert N. Kirchdoerfer et al.
NATURE COMMUNICATIONS (2019)
Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
Maria L. Agostini et al.
JOURNAL OF VIROLOGY (2019)
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
Mart Toots et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Recent progress in the discovery of inhibitors targeting coronavirus proteases
Haofeng Wang et al.
VIROLOGICA SINICA (2016)
The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
Yahira M. Baez-Santos et al.
ANTIVIRAL RESEARCH (2015)
Suppressive effects of androgens on the immune system
Abhishek Trigunaite et al.
CELLULAR IMMUNOLOGY (2015)
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Jasper Fuk-Woo Chan et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases
Yahira M. Baez-Santos et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
Jason Haffizulla et al.
LANCET INFECTIOUS DISEASES (2014)
The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
Jared M. Lucas et al.
CANCER DISCOVERY (2014)
The newly emerged SARS-Like coronavirus HCoV-EMC also has an Achilles' heel: current effective inhibitor targeting a 3C-like protease
Zhilin Ren et al.
PROTEIN & CELL (2013)
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
BL Haagmans et al.
NATURE MEDICINE (2004)
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome - A preliminary study
MR Loutfy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor
HT Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Lopinavir/ritonavir - A review of its use in the management of HIV infection
RS Cvetkovic et al.
DRUGS (2003)